119357-34-5

Usage

Uses

Used in Pharmaceutical Industry:
rac N-DideMethyl Dapoxetine is used as an active pharmaceutical ingredient for the development of antidepressant medications. Its role as a selective serotonin reuptake inhibitor helps in modulating the levels of serotonin in the brain, which is crucial for managing depression and related disorders.
Used in Research and Development:
In the field of pharmaceutical research and development, rac N-DideMethyl Dapoxetine serves as a valuable compound for studying the mechanisms of SSRI antidepressants and their effects on the central nervous system. This understanding can lead to the development of more effective and targeted treatments for depression and other related conditions.
Used in Drug Delivery Systems:
Similar to Gallotannin, rac N-DideMethyl Dapoxetine can also benefit from novel drug delivery systems to enhance its bioavailability, delivery, and therapeutic outcomes. By employing various organic and metallic nanoparticles as carriers, the limitations of rac N-DideMethyl Dapoxetine can be overcome, leading to improved efficacy in treating depression and related disorders.

Upstream product

• 3646-50-2 3-Amino-3-phenylpropionic acid 
• 100-52-7 benzaldehyde 
• 14593-04-5 3-amino-3-phenyl-1-propanol 
• 41198-42-9 3-(naphthalen-1-yloxy)-1-phenylpropan-1-one 

Downstream Products

• 147199-40-4 Didesmethyldapoxetine 
• 1071929-03-7 Dapoxetine hydrochloride 
• 119356-77-3 dapoxetine 
• 119356-76-2 N,N-dimethylamino-3-(naphthyl-1-oxy)-1-phenylprop-1-amine 
• 119357-36-7 (R)-N,N-dimethyl-α-[2-(1-naphthyloxy)ethyl]benzylamine 

Relevant academic research and scientific papers

Development of novel triazole based dendrimer supported spiroborate chiral catalysts for the reduction of (: E)-O-benzyl oxime: An enantioselective synthesis of (S)-dapoxetine

Novel dendrimer supported spiroborate catalysts 2 and 3 have been synthesized using a click reaction as a key step. The catalytic efficiency of the catalysts have been verified with reduction of (E)-O-benzyl oxime 13 as a model substrate. Catalyst 3 was found to be better than catalyst 2 as the chemical yield and enantiomeric excess were significantly high with the former catalyst. Thus, catalyst 3 has been successfully used in the efficient synthesis of (S)-dapoxetine 14 with 94% ee and 46% overall yield in three steps. These catalysts could be easily recovered from the reaction solution by the solvent precipitation technique and could be reused five times without significant loss of activity and enantioselectivity.

A S - west reaches anchors the sandbank and its salt synthesis method

The invention discloses a synthetic method for S-dapoxetine. The synthetic method comprises the following steps: (1) resolving 1-phenyl-3-(naphthyl-1-oxy)propylamine for at least once with a resolving agent to obtain a resolved mixed system; (2) separating the resolved mixed system to obtain S-1-phenyl-3-(naphthyl-1-oxy)propylamine, and recycling mother liquor; (3) performing methylation on the S-1-phenyl-3-(naphthyl-1-oxy)propylamine to obtain S-dapoxetine. Compared with the conventional industrial production method, residual intermediate (R)-phenyl-3-(naphthyl-1-oxy)propylamine in the resolved mother liquor is firstly recycled on the basis of the prior art, then resolved again through D-(-) tartaric acid after racemization, and recycled, so that the yield is increased, the product waste is avoided, and the economic benefits are improved.